Ahead of today's review of Retacrit, Pfizer’s proposed biosimilar of Amgen’s epoetin alfa (Epogen) by the FDA’s Oncologic Drugs Advisory Committee (ODAC), committee members expressed positive views of the drug’s similarity to the reference drug Epogen.
In a review document posted on the FDA website, agency reviewers called Pfizer’s product “highly similar” to Amgen’s Epogen (and Johnson & Johnson’s Procrit, which is the same drug but is marketed for different uses under a licensing arrangement with a California biotech), and wrote that despite minor differences in clinically inactive components, the similarity stood. They further state that there are no clinically meaningful differences between the biosimilar and reference products in terms of the safety, purity, and potency. Pfizer hopes to gain approvals for Retacrit in each of Epogen’s 4 indications:
If approved, Retacrit will be Pfizer’s second biosimilar to be marketed in the United States. Inflectra, Pfizer’s biosimilar of infliximab (Remicade), was approved in November 2016. If approved, Retacrit would also be the second biosimilar approval to compete directly with an Amgen reference biologic product. Amgen is already facing competition from filgrastim-sndz (Zarxio), an approved biosimilar of filgrastim (Neupogen).
Retacrit’s approval, while likely, is not assured. Retacrit has faced prior regulatory denial: in 2015, the FDA issued a complete response letter to Pfizer following Pfizer’s acquisition of Hospira, which had developed the drug. And even if Retacrit is approved, a legal battle with Amgen looms over the marketing of Retacrit. Amgen is suing in federal court to block the launch of Retacrit, alleging that Hospira provided Amgen with notice of commercial launch too soon in the “patent dance” process laid out in the Biologics Price Competition and Innovation Act.
Epogen and Procrit are blockbuster drugs, with each earning over $1 billion in worldwide sales in 2016. Another Epogen biosimilar is likely to add to the competition with Amgen: Sandoz is also preparing to submit an application to the FDA for its Epogen biosimilar.
*Update: Pfizer announced in a press release that ODAC recommended approval of the company's epoetinalpha biosimilar across all the indications listed above. the recommendation will come into play when the FDA evaluates Pfizer's Biologics Licence Application for the proposed epoetin alfa biosimilar.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.